Edition:
United States

Abbott Laboratories (ABT)

ABT on New York Consolidated

48.82USD
18 Aug 2017
Change (% chg)

$-0.47 (-0.95%)
Prev Close
$49.29
Open
$49.10
Day's High
$49.17
Day's Low
$48.76
Volume
626,266
Avg. Vol
6,249,576
52-wk High
$51.13
52-wk Low
$37.38

Select another date:

Wed, Aug 16 2017

BRIEF-Enzo Biochem says federal judge in a U.S. Court has entered an order in action entitled Enzo Life Sciences v. Abbott Laboratories ​

* Enzo Biochem says ‍a federal judge in a U.S. Court has entered an order in action entitled Enzo Life Sciences, Inc. v. Abbott Laboratories - sec filing​

BRIEF-Abbott Laboratories says co & North West London Pathology signed a $252 mln managed equipment services contract

* Abbott Laboratories- Co & North West London Pathology signed a $252 million managed equipment services contract

BRIEF-Abbott announces extension of cash tender offer for all outstanding shares of series B convertible perpetual preferred stock of Alere Inc

* Abbott announces extension of cash tender offer for all outstanding shares of series B convertible perpetual preferred stock of Alere Inc

BRIEF-Roxwood Medical enters into an exclusive agreement with Abbott for distribution of roxwood products in United States

* Roxwood Medical - entered into an exclusive agreement with Abbott for distribution of Roxwood Products in United States Source text for Eikon: Further company coverage:

BRIEF-Alere Inc enters into purchase agreement with Siemens Diagnostics ​‍​

* Says ‍on July 21, 2017, Alere entered into purchase agreement with Siemens Diagnostics Holding II B.V. ​‍​

Abbott profit forecast gets a lift from St. Jude integration

Abbott Laboratories raised its full-year profit forecast as the company benefits from its St. Jude Medical acquisition, and said it was confident that the Alere purchase would close this year, sending its shares to a near two-year high.

UPDATE 3-Abbott profit forecast gets a lift from St. Jude integration

* Shares rise as much as 2.8 pct to $50.83 (Adds conference call details; updates shares)

Abbott's quarterly profit halves as costs soar

July 20 Diversified healthcare company Abbott Laboratories reported a 55 percent drop in quarterly profit on Thursday, hurt by higher costs.

BRIEF-Abbott says commences tender offer for Series B preferred stock of Alere

* Abbott commences cash tender offer for all outstanding shares of series b convertible perpetual preferred stock of Alere Inc

Abbott must pay John Hancock $33 million over drug development deal

Abbott Laboratories Inc must pay John Hancock Life Insurance Co over $33 million in a long-running dispute over a failed investment the insurer made to support the development of pharmaceutical products, a federal appeals court has ruled.

Select another date: